drugset / Trial / NCT00572260
A Pilot Study of Daptomycin for Antimicrobial Prophylaxis
Phase 4
Terminated
11 enrolled
Duke University
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · collab
NaSingle-groupOpen-label
Summary
The goals of the study are to evaluate the feasibility of using daptomycin as a prophylactic antimicrobial agent in patients undergoing cardiac surgery, to determine the rates of surgical site infection, and to evaluate the occurrence of adverse events.
Timeline
- Start
- 2008-01
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daptomycin | Other / unclassified | 6 mg/kg | Intravenous |
Indications
No indication recorded.